Larson Financial Group’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.07K | Sell |
550
-19
| -3% | -$175 | ﹤0.01% | 2050 |
|
|
2025
Q1 | $4.88K | Sell |
569
-8
| -1% | -$69 | ﹤0.01% | 1875 |
|
|
2024
Q4 | $6.2K | Sell |
577
-638
| -53% | -$6.85K | ﹤0.01% | 1609 |
|
|
2024
Q3 | $6.9K | Hold |
1,215
| – | – | ﹤0.01% | 1595 |
|
|
2024
Q2 | $5.13K | Hold |
1,215
| – | – | ﹤0.01% | 1436 |
|
|
2024
Q1 | $6.18K | Buy |
1,215
+205
| +20% | +$1.04K | ﹤0.01% | 1146 |
|
|
2023
Q4 | $9.4K | Hold |
1,010
| – | – | ﹤0.01% | 1032 |
|
|
2023
Q3 | $6.62K | Hold |
1,010
| – | – | ﹤0.01% | 1107 |
|
|
2023
Q2 | $8.21K | Hold |
1,010
| – | – | ﹤0.01% | 991 |
|
|
2023
Q1 | $8.66K | Buy |
1,010
+15
| +2% | +$129 | ﹤0.01% | 963 |
|
|
2022
Q4 | $9.21K | Buy |
995
+445
| +81% | +$4.12K | ﹤0.01% | 884 |
|
|
2022
Q3 | $6K | Hold |
550
| – | – | ﹤0.01% | 908 |
|
|
2022
Q2 | $6K | Hold |
550
| – | – | ﹤0.01% | 817 |
|
|
2022
Q1 | $7K | Hold |
550
| – | – | ﹤0.01% | 722 |
|
|
2021
Q4 | $10K | Hold |
550
| – | – | ﹤0.01% | 679 |
|
|
2021
Q3 | $10K | Hold |
550
| – | – | ﹤0.01% | 585 |
|
|
2021
Q2 | $13K | Hold |
550
| – | – | ﹤0.01% | 507 |
|
|
2021
Q1 | $8K | Hold |
550
| – | – | ﹤0.01% | 578 |
|
|
2020
Q4 | $3K | Hold |
550
| – | – | ﹤0.01% | 592 |
|
|
2020
Q3 | $3K | Hold |
550
| – | – | ﹤0.01% | 559 |
|
|
2020
Q2 | $3K | Hold |
550
| – | – | ﹤0.01% | 520 |
|
|
2020
Q1 | $2K | Hold |
550
| – | – | ﹤0.01% | 421 |
|
|
2019
Q4 | $1K | Hold |
550
| – | – | ﹤0.01% | 486 |
|
|
2019
Q3 | $2K | Hold |
550
| – | – | ﹤0.01% | 426 |
|
|
2019
Q2 | $2K | Hold |
550
| – | – | ﹤0.01% | 377 |
|
|
2019
Q1 | $2K | Hold |
550
| – | – | ﹤0.01% | 368 |
|
|
2018
Q4 | $1K | Buy |
+550
| New | +$1K | ﹤0.01% | 388 |
|